AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma

AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma

Abstract Background Currently, multiple myeloma (MM) is still an incurable plasma cell malignancy in urgent need of novel therapeutic targets and drugs. Methods Bufalin was known as a highly toxic but effective anti-cancer compound. We used Bufalin as a probe to screen its potential targets by prote...

Full description

Bibliographic Details
Main Authors: Chunyan Gu, Yajun Wang, Lulin Zhang, Li Qiao, Shanliang Sun, Miaomiao Shao, Xiaozhu Tang, Pinggang Ding, Chao Tang, Yuhao Cao, Yanyan Zhou, Mengjie Guo, Rongfang Wei, Nianguang Li, Yibei Xiao, Jinao Duan, Ye Yang
Format: Article
Language:English
Published: BMC 2022-01-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Multiple myeloma
AHSA1
HSP90
Bufalin
Proliferation
Drug resistance
Online Access:https://doi.org/10.1186/s13046-021-02220-1

Internet

https://doi.org/10.1186/s13046-021-02220-1

Similar Items